TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
WALTHAM, Mass., Feb. 21, 2017 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Raymond James 38th Annual Institutional Investors Conference at the JW Marriott Grand Lakes in Orlando, Florida on Monday, March 6, 2017. Tim Pearson, EVP and CFO of TESARO, will present at 8:40 AM ET and participate in meetings with investors.
- The Barclays Global Healthcare Conference at the Loews Hotel in Miami, Florida on Wednesday, March 15, 2017. Lonnie Moulder, CEO of TESARO, will participate in an analyst-led moderated Q&A from 3:50 to 4:15 PM ET and in meetings with investors.
Live webcasts of the presentations at the Raymond James and Barclays conferences will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
